Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor

British Journal of Cancer

Volumn 75, Issue 11, 1997, Pages 1575-1584

  Schmidt, M ^a,b   Vakalopoulou, E ^c   Schneider, D W ^d   Wels, W ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BAYER PHARMA AG   (Germany)

^d BAYER AG   (Germany)

Author keywords

Directed tumour therapy; Epidermal growth factor receptor; Exotoxin A; Single chain Fv

Indexed keywords

CELL SURFACE PROTEIN; CYTOTOXIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; SCFV(14E1) ETA; TUMOR GROWTH FACTOR ALPHA ETA; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; EPITHELIUM TUMOR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TARGET CELL; TUMOR CELL;

EID: 0031011597     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.270     Document Type: Article

References (24)

1. Beerli RR, Wels W and Hynes NE (1994) Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Comm 204: 666-672
2. Chaudhary VK, Fitzgerald DJ, Adhya S and Pastan I (1987) Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin. Proc Natl Acad Sci USA 84: 4538-4542
3. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE and Schlom J (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197
4. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH (1987) Synthesis of messenger RNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712
5. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J and Dickson RB (1989) Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3: 1830-1838
6. Fan Z, Mendelsohn J, Masui H and Kumar R (1993a) Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem 268: 21073-21079
7. Fan Z, Masui H, Altas I and Mendelsohn J (1993b) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-4328
8. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED, Oliff AE and Pastan IH (1995) Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Rex 1: 57-61
9. Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98
10. Harwerth IM, Wels W, Marte BM and Hynes NE (1992) Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267: 15160-15167
11. Köhler G and Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497
12. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G and Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic nude mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007
13. Ogata M, Fryling CM, Pastan I and Fitzgerald DJ (1992) Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 267: 25396-25401
14. Pai LH, Gallo MG, Fitzgerald DJ and Pastan I (1991) Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res 51: 2808-2812
15. Peles E and Yarden Y (1993) Neu and its ligands: from an oncogene to neural factors. Bioessays 15: 815-824
16. Schmidt M and Wels W (1996) Targeted inhibition of tumor cell growth by a bispecific single chain toxin containing an antibody domain and TGFα. Br J Cancer 74: 853-862
17. Schmidt M, Hynes NE, Groner B and Wels W (1996) A bivalent single chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer 65: 538-546
18. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 266: 21118-21124
19. Siegall CB, Xu YH, Chaudhary VK, Adhya S, Fitzgerald D and Pastan I (1989) Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin. Faseb J 3: 2647-2652
20. Van de Vijver MJ, Kumar R and Mendelsohn J (1991) Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem 266: 7503-7508
21. Weber W. Gill GN and Spiess J (1984) Production of an epidermal growth factor receptor-related protein. Science 224: 294-297
22. Weis W, Harwerth IM, Zwickl M, Hardman N, Groner B and Hynes NE (1992a) Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology 10: 1128-1132
23. Wels W, Harwerth IM, Mueller M, Groner B and Hynes NE (1992b) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52: 6310-6317
24. erbH-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 60: 137-144